Cargando…
Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema
BACKGROUND: Our research focuses on the co-creation of value in healthcare with reference to a case of hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE). Our work is mainly based on the concept of value co-creation in healthcare. The aim of this study is to assess the impact of an alte...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053759/ https://www.ncbi.nlm.nih.gov/pubmed/30029666 http://dx.doi.org/10.1186/s12913-018-3389-y |
_version_ | 1783340885128249344 |
---|---|
author | Spanò, Rosanna Di Paola, Nadia Bova, Maria Barbarino, Alessandro |
author_facet | Spanò, Rosanna Di Paola, Nadia Bova, Maria Barbarino, Alessandro |
author_sort | Spanò, Rosanna |
collection | PubMed |
description | BACKGROUND: Our research focuses on the co-creation of value in healthcare with reference to a case of hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE). Our work is mainly based on the concept of value co-creation in healthcare. The aim of this study is to assess the impact of an alternative treatment strategy – self-administration – by focusing on treatment outcomes and costs to understand if innovative therapeutic solutions can create value for patients and healthcare systems. METHODS: This paper compares home-based and hospital-based therapeutic strategies (independent of treatment type) with a cost minimization analysis. It encompasses compliance issues and focuses on both payer and societal perspectives, also benefiting from an operationalization of the service-dominant logic model for healthcare delivery. Data were collected over a 6-month period (August 2014–January 2015) through monthly patient interviews. Archival data were used for variable measurement. RESULTS: Thirty-nine out of 62 patients enrolled in the study, experienced at least one HAE attacks, equally distributed between home and hospital-based strategies. No evidence of correlation between therapeutic strategy and disease severity score (p = 0.351), compliance (p = 0.399), and quality of life (p = 0.971), were found. Total direct cost per attack amounts to € 1224 for home-based strategy with respect to € 1454 for hospital-based strategy, with a savings of € 230. The economic advantage of the home-based strategy almost doubles if the societal perspective was considered due to a further savings of €169 (less missed work/school days and no travel expenses). CONCLUSIONS: Our study suggests that home-based therapies represent a feasible strategy for managing C1-INH-HAE and may result in lower costs and increased value for both patients and the healthcare systems. The findings are relevant to the debate on and extend the extant literature to provide a broader view of value co-creation dynamics for home-based therapies in healthcare and their positive effects. The insights are relevant to practitioners and policy makers. |
format | Online Article Text |
id | pubmed-6053759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60537592018-07-23 Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema Spanò, Rosanna Di Paola, Nadia Bova, Maria Barbarino, Alessandro BMC Health Serv Res Research Article BACKGROUND: Our research focuses on the co-creation of value in healthcare with reference to a case of hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE). Our work is mainly based on the concept of value co-creation in healthcare. The aim of this study is to assess the impact of an alternative treatment strategy – self-administration – by focusing on treatment outcomes and costs to understand if innovative therapeutic solutions can create value for patients and healthcare systems. METHODS: This paper compares home-based and hospital-based therapeutic strategies (independent of treatment type) with a cost minimization analysis. It encompasses compliance issues and focuses on both payer and societal perspectives, also benefiting from an operationalization of the service-dominant logic model for healthcare delivery. Data were collected over a 6-month period (August 2014–January 2015) through monthly patient interviews. Archival data were used for variable measurement. RESULTS: Thirty-nine out of 62 patients enrolled in the study, experienced at least one HAE attacks, equally distributed between home and hospital-based strategies. No evidence of correlation between therapeutic strategy and disease severity score (p = 0.351), compliance (p = 0.399), and quality of life (p = 0.971), were found. Total direct cost per attack amounts to € 1224 for home-based strategy with respect to € 1454 for hospital-based strategy, with a savings of € 230. The economic advantage of the home-based strategy almost doubles if the societal perspective was considered due to a further savings of €169 (less missed work/school days and no travel expenses). CONCLUSIONS: Our study suggests that home-based therapies represent a feasible strategy for managing C1-INH-HAE and may result in lower costs and increased value for both patients and the healthcare systems. The findings are relevant to the debate on and extend the extant literature to provide a broader view of value co-creation dynamics for home-based therapies in healthcare and their positive effects. The insights are relevant to practitioners and policy makers. BioMed Central 2018-07-20 /pmc/articles/PMC6053759/ /pubmed/30029666 http://dx.doi.org/10.1186/s12913-018-3389-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Spanò, Rosanna Di Paola, Nadia Bova, Maria Barbarino, Alessandro Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema |
title | Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema |
title_full | Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema |
title_fullStr | Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema |
title_full_unstemmed | Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema |
title_short | Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema |
title_sort | value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053759/ https://www.ncbi.nlm.nih.gov/pubmed/30029666 http://dx.doi.org/10.1186/s12913-018-3389-y |
work_keys_str_mv | AT spanorosanna valuecocreationinhealthcareevidencefrominnovativetherapeuticalternativesforhereditaryangioedema AT dipaolanadia valuecocreationinhealthcareevidencefrominnovativetherapeuticalternativesforhereditaryangioedema AT bovamaria valuecocreationinhealthcareevidencefrominnovativetherapeuticalternativesforhereditaryangioedema AT barbarinoalessandro valuecocreationinhealthcareevidencefrominnovativetherapeuticalternativesforhereditaryangioedema |